Time-Critical Enrolment
In an untreated acute ischaemic stroke, around 1.9 million neurons are lost every minute. We build screening, randomisation and site workflows that fit inside the emergency pathway, not around it.

Clinical evidence for stroke, neurovascular, neuromodulation and neuro-monitoring devices
Neurology device studies bring their own clinical and operational challenges, from treatment windows measured in minutes to consent in patients who cannot give it, sham-controlled designs and long-term follow-up of active implants. QbD Group combines medical device CRO execution with regulatory and scientific expertise to build the evidence for your neurological device, from strategy to post-market follow-up.
Neurological Endpoints
A neurology medical device CRO is a contract research organisation that designs and runs clinical investigations for devices that diagnose, monitor or treat conditions of the brain, spinal cord and nerves. QbD Clinical is a European CRO that works only on medical devices, IVD and companion diagnostics, with neurology as one of three core therapeutic areas. Over the past five years we have supported 49 NeuroTech clinical trials.
We support stroke and neurovascular devices, neurostimulation and neuromodulation systems, epilepsy technologies, neuro-monitoring and diagnostic devices, and neurology software (SaMD), from first-in-human and pivotal investigations through post-market clinical follow-up (PMCF).
Our objective is to generate the evidence you need for EU MDR compliance, FDA submissions and your next development milestone, through study designs that are scientifically sound and workable at the bedside.
Neurology Track Record
49
NeuroTech clinical trials supported in the past five years
23
Epilepsy trials
8
Cerebrovascular disease and stroke trials
28
Trials involving implantable and reconstructive devices
Pivotal, first-in-human and post-market experience across Europe and the US, including a 277-subject pivotal stroke study.
Protocol Details
Neurology trials succeed or fail on details a generalist CRO can miss. We plan for them from day one.
In an untreated acute ischaemic stroke, around 1.9 million neurons are lost every minute. We build screening, randomisation and site workflows that fit inside the emergency pathway, not around it.
EU MDR sets specific rules for investigations in emergency situations (Article 68), incapacitated subjects (Article 64) and minors (Article 65). We design consent and deferred-consent procedures that ethics committees and national authorities accept.
Functional and clinical scales such as the modified Rankin Scale (mRS), NIHSS and reperfusion grades (mTICI), seizure diaries and validated quality-of-life measures, measured consistently across sites.
CT, MRI and angiography assessments aligned through core-lab reading, so imaging endpoints stay consistent between centres and countries.
Neuromodulation and neurostimulation studies often need sham arms and blinded assessors. We design control strategies that hold up to scrutiny from Notified Bodies and the FDA.
Implanted neurostimulators and neurovascular implants are usually Class III. We plan PMCF, device performance tracking and safety reporting for the full life of the implant.
Connected Device Disciplines
Neurology devices increasingly combine an implant or catheter with software, connectivity and AI. QbD Group brings the disciplines together, so you are not stitching vendors together across the lifecycle.
Study design, operations, monitoring, imaging coordination, data management and CSR.
EU MDR strategy, Notified Body coordination, CER and PMCF, authority and ethics submissions.
QMS, ISO 13485 and audit-ready documentation.
IEC 62304, validation and AI-enabled software for neuro-monitoring and diagnostics.
For non-EU sponsors running clinical investigations in Europe.
Stroke and Neurotechnologies
Indication
Study Type
Regions
Subjects
Services
Indication
Study Type
Regions
Services
Indication
Study Type
Regions
Subjects
Services
Indication
Study Type
Subjects
Outcome
Regions
Services
Authority Response Experience
Where authority questions arose, our experience turned them into fast, compliant outcomes.
Challenge: The Belgian Competent Authority (FAGG) raised concerns about potential bias in the design of a high-risk first-in-human investigation.
QbD Group Solution: We addressed the study-design concerns and set up a Data Safety Monitoring Board (DSMB) to provide independent oversight.
Competent Authority feedback resolved.
Challenge: A clinical investigation submission was rejected as incomplete.
QbD Group Solution: We rapidly completed the package, including updated insurance certificates, ICF updates and PI clarifications.
Scientific Counsel
Our Medical Advisory Board brings together experienced life sciences professionals who provide expert guidance on clinical strategy, patient safety, scientific rigour, and regulatory compliance.

Full Professor & Head of Paediatric Neurology
Areas of Expertise
Strategic & Scientific Advice
Clinical Study Support
Clinical Evidence Support
Therapeutic Training for QbD Group Employees
End-to-End Delivery
Build the right evidence package from study design to PMCF, with QbD Group’s clinical, regulatory and wider MedTech expertise under one roof.
01
02
03
04
05
06
07
08
On-Demand Webinar
Sponsor Planning Guidance

Whether you are refining your clinical strategy or launching a pivotal stroke or neuromodulation study, our clinical and regulatory experts are ready to support your MedTech journey, from gap assessment to full CRO delivery.